What do systematic reviews say?

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

Oral plus nebulised antibiotics showed no clear difference in adverse effects of treatment compared with oral antibiotics plus nebulised placebo (low certainty).

• Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  OR 3 [0.11, 79.91]
  1 study · 29 participants
  Low

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 223 participants
  Moderate

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in adverse effects of antibiotics: number of participants experiencing… compared with TNS plus oral placebo (moderate certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 1.05 [0.96, 1.14]
  1 study · 221 participants
  Moderate

Oral ciprofloxacin and inhaled colistin vs no treatment

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin

It is very uncertain whether oral ciprofloxacin and inhaled colistin changes adverse effects of antibiotics: severe cough compared with inhaled tobramycin (TNS) (very low certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  OR 0.32 [0.01, 8.24]
  1 study · 58 participants
  Very low

Intervention not reported

• Growth hormone therapy for people with thalassaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Up to 10 days postoperative
  RD 0.034 [-0.32, 0.38]
  2 studies · 59 participants
  Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD 0.00 [-0.04, 0.04]
  2 studies · 128 participants
  Moderate

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.97
  1 study · 285 participants
  Moderate